This activity is expired and is no longer available for CME credit.


Anti-VEGF for Retinopathy of Prematurity

Author(s)/Faculty: Audina M. Berrocal, MD
Release Date: 5/23/2016Expiration Date: 5/15/2019
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Retinopathy of prematurity (ROP) continues to be a leading cause of blindness in infants in developing and developed countries. Traditionally, treatment options for ROP have been laser therapy or cryotherapy but recently intravitreal anti-VEGF therapy has been used. There is an increasing concern regarding the use of intravitreal anti-VEGF drugs for the treatment of ROP. In this activity, leading ophthalmologists will discuss the latest advances in using anti-VEGF agents to treat ROP.